509 results
Page 4 of 26
CORRESP
j3e239 0gg
6 Jan 21
Correspondence with SEC
12:00am
UPLOAD
znk2vj7vnsbxzj
23 Dec 20
Letter from SEC
12:00am
8-K
EX-99.1
nz0mys8wxurjq
21 Dec 20
Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders
8:39am
8-K/A
EX-99.1
5cpmsf
10 Dec 20
Financial Statements and Exhibits
4:13pm
8-K
u7xk7 xfx5r
3 Dec 20
Other Events
12:00am
8-K
ir7zls
23 Nov 20
Other Events
8:32am
8-K
cz0wn6b
30 Oct 20
Amendments to Articles of Incorporation or Bylaws
4:07pm
8-K
EX-99.1
k93aa78sszuae9862gx2
30 Oct 20
Ligand Reports Third Quarter 2020 Financial Results
8:03am
8-K
561ni2jfu
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
8-K
EX-99.1
5xlkp tks4w
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
8-K
EX-2.1
08p72ceq
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
8-K
EX-99.3
oavp trnsl8nuh
1 Oct 20
Contingent Value Rights Agreement
8:42am
8-K
EX-99.1
gpsa2iqjikq58r2nxd5
1 Oct 20
Contingent Value Rights Agreement
8:42am
SC TO-T/A
EX-99
pnrjtdvf2jb
30 Sep 20
Third party tender offer statement (amended)
8:06am
SC TO-T/A
1t03jva6 aws
16 Sep 20
Third party tender offer statement (amended)
6:05am
SC TO-T/A
wahyx8egpe
11 Sep 20
Third party tender offer statement (amended)
6:07am